#rhapsido — Public Fediverse posts

https://www.europesays.com/ch/126761/ Yuhan to Distribute Novartis Hives Drug Rhapsido in Korea #BTKInhibitor #ChronicSpontaneousUrticaria #lesigercept #Novartis #NovartisKorea #remibrutinib #Rhapsido® #Yuhan

https://www.europesays.com/ch/89238/ FDA clears Novartis’ oral drug for chronic hives #ChronicSpontaneousUrticaria #ImmunologyAndInflammation #Novartis #PharmaNews #RegulatoryApproval #remibrutinib #Rhapsido®

https://www.europesays.com/ch/82275/ Novartis RemIND data at EAACI show Rhapsido® potential as first targeted therapy for chronic inducible urticaria (CIndU) #(CIndU) #as #at #chronic #data #EAACI #first #for #inducible #Novartis #potential #RemIND #Rhapsido® #Show #targeted #therapy #urticaria

https://www.europesays.com/ch/79326/ Novartis to highlight Rhapsido® data across multiple immune-mediated diseases at EAACI Congress 2026 #2026 #Across #at #Congress #data #Diseases #EAACI #highlight #ImmuneMediated #multiple #Novartis #Rhapsido® #to

https://www.europesays.com/ch/64392/ Novartis Weighs US Buildout And Rhapsido Launch In Growth Outlook #ChronicSpontaneousUrticaria #Europe #EuropeanCommission #Manufacturing #Novartis #ResearchFacilities #Rhapsido® #therapies

Novartis Rhapsido® receives European Commission approval as first oral targeted treatment for chronic spontaneous urticaria

Significant improvements as early as Week 1, favorable safety profile and no liver safety concerns in REMIX 1 & 2 studies of highly…
#Europe #EU #EuropeanCommission #asfirstoral #chronic #Commissionapproval #for #Novartis #receivesEuropean #Rhapsido® #spontaneous #targeted #treatment #urticaria
https://www.europesays.com/europe/23672/

https://www.europesays.com/ch/56243/ Novartis Rhapsido® receives European Commission approval as first oral targeted treatment for chronic spontaneous urticaria  #as first oral #chronic #Commission approval #for #Novartis #receives European #Rhapsido® #spontaneous #targeted #treatment #urticaria